Prospective, Open-label, Non-significant Risk, Multicenter Study Comparing the Polyp Detection of the Study Device to That of the Colonoscopy Reference

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45-75
SponsorCapso Vision, Inc.

About this trial

Note: This is the same study protocol as NCT04607746 with slight changes to how the videos will be read and a 2nd generation capsule is being studied.

The purpose of this study is to evaluate the safety and effectiveness of CapsoCam® Colon (CV-3) endoscope system for the detection of colonic polyps and to show that AI-based CADe improves the polyp-detection accuracy and efficiency of capsule video readers. It will use colonoscopy results as a reference.

The participant will:

1. prep for and swallow a study capsule and then 2. prep for and undergo a colonoscopy either the following day or 3-6 weeks later

Eligibility criteria

Qualifiers

45-75 years of age

Committed to undergo a colonoscopy.

Choose to participate and must have signed the IRB-approved informed consent document and agreed to release colonoscopy images and results report to Sponsor

Disqualifiers

Colonoscopy or CT-colonography within the past 5 years that demonstrated no polyps

Has contraindication for capsule endoscopy or colonoscopy

Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high-risk genetic syndrome

Subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative colitis or Crohn's disease

Trial design

Treatments tested in this trial

  • Capsule swallow

Treatment groups

330 Participants
are divided into 1 treatment group

Sponsors and collaborators